Search Results - "Haslund, C.A."

Selection for proton radiotherapy of grade 1–3 glioma patients by Byskov, C.S., Muhic, A., Dahlrot, R.H., Haslund, C.A., Guldberg, T.L., Høyer, M., Nyström, P.W., Dysager, L., Hansen, S., Haldbo-Classen, L., Trip, A.K., Lassen-Ramshad, Y., Weber, B., Lukacova, S., Hansen, C.R., Kallehauge, J.F.

“…•National workshops ensure consensus when neurooncologists select patients with brain cancer for proton therapy.•A logistic regression-based model was…”
Get full text

852P Does sex affect the efficacy of immune checkpoint inhibitors? A national Danish melanoma study by Petersen, S.K., Schmidt, H., Ellebæk, E., Haslund, C.A., Hansen, C.R., Bastholt, L.

Get full text

1156P Immune-related adverse events in a nationwide cohort of melanoma patients treated with adjuvant anti-PD1: Seasonal variation and association with outcome by Ellebæk, E., Jurlander, R.S., Guldbrandt, L.M., Holmstroem, R.B., Donia, M., Haslund, C.A., Schmidt, H., Bastholt, L., Ruhlmann, C.H., Svane, I-M.

Get full text

1137P Treatment strategies and survival outcomes in a nationwide, population-based cohort of patients with melanoma brain metastases: The role of planned shift in systemic therapy and postoperative stereotactic radiotherapy by Pedersen, S., Johansen, E.L., Højholt, K., Wett, M.H., Mogensen, A.M., Petersen, S.K., Friis, R.B., Donia, M., Haslund, C.A., Schmidt, H., Bastholt, L., Svane, I-M., Ellebæk, E.

Get full text

1071P A nationwide, real-life study of outcome and quality of life after the introduction of adjuvant immunotherapy for Danish melanoma patients by Ellebaek, E., Holmstrøm, R.B., Ruhlmann, C.H., Schmidt, H., Haslund, C.A., Donia, M., von Heymann, A., Johansen, C., Bastholt, L., Svane, I.M.

Get full text

500O Trotabresib (CC-90010) combined with concomitant temozolomide (TMZ) plus radiotherapy (RT) and adjuvant TMZ in patients (pts) with newly diagnosed primary glioblastoma (ndGBM): Updated results from a phase Ib/II study by Villar, M. Vieito, Sánchez, J.M. Sepúlveda, Garcia, V. Moreno, Lombardi, G., Stradella, A., Dahlrot, R.H., Haslund, C.A., Geurts, M., Pineda, E., Brandal, P., De Vos, F.Y.F.L., Vaz Salgado, M.A., Garcia, M. Martinez, Macchini, M., Amoroso, B., Sanchez, T., Hanna, B., Li, X., Nikolova, Z., Simonelli, M.

Get full text

109P Prognosis of patients with metastatic melanoma with initial stable disease during treatment with anti-PD-1 monotherapy by Noringriis, I.M., Donia, M., Bastholt, L., Schmidt, H., Haslund, C.A., Ellebæk, E., Svane, I-M.

Get full text

573P Role of CA125 in patients included in the DESKTOP III/ENGOT-ov20 trial by Lecuru, F., Sehouli, J., Vergote, I.B., Reuss, A., Classe, J-M., Hillemanns, P., Greggi, S., Mirza, M.R., Brachet, P.E., Follana, P., Raban, N., Hasenburg, A., Zang, R., Lindemann, K., Kim, J-W., Poveda, A., Raspagliesi, F., Haslund, C.A., du Bois, A., Harter, P.

Get full text

PH-0608 A national study on the inter-observer variability in delineation of organs at risk in the brain by Lorenzen, E.L., Kallehauge, J.F., Byskov, C.S., Dahlrot, R.H., Haslund, C.A., Guldberg, T.L., Lassen-Ramshad, Y., Lukacova, S., Muhic, A., Nyström, P.W., Haldbo-Classen, L., Bahij, I., Larsen, L., Weber, B., Rønn Hansen, C., Hansen, C.R.

Get full text

50P Clinical impact of actionable molecular variants disclosed in late-stage cancer patients by tumor whole-exome sequencing in a prospective single-institution study by Mapendano, C.K., Nøhr, A.K., Carus, A., Lorincz, T., Oestergaard, L. Poulsen, Haslund, C.A., Pagh, A., Sønderkærd, M., Bøgsted, M., Pedersen, I.S., Ladekarl, M.

Get full text

51P Efficacy and safety by time to maintenance therapy treatment initiation in PRIMA/ENGOT-OV26/GOG-3012 by Haslund, C.A., Willmott, L.J., Pérez, M.J. Rubio, Cloven, N., Van den Bulck, H.F.M., Moore, R.G., Pisano, C., O'Cearbhaill, R.E., Selle, F., Pothuri, B., Harter, P., Ghamande, S., Bruchim, I., Disilvestro, P., Ginesta, M.P. Barretina, Koliadi, A., Malinowska, I., York, W., González-Martín, A., Monk, B.J.

Get full text